Company Overview
Snapshot
Founded in March 2022 by Ravit Netzer and Adi Goldenzweig, Scala Biodesign operates with 11–50 employees. The company has raised $21.5 million across two funding rounds from three investors, including lead investor Grove Ventures.
Business overview
Scala Biodesign develops advanced computational protein design solutions to address complex protein development challenges. The company's technology accelerates the development process, increases success rates, and reduces R&D efforts for proteins, enabling partners to pursue challenging projects previously considered unfeasible. Scala Biodesign serves the pharmaceutical, chemical, diagnostics, and food sectors, operating within the Health Tech & Life Sciences sector, with a focus on drugs discovery and development.
Strategic signal
In March 2026, Scala Biodesign successfully closed an A Round, with Grove Ventures leading the investment. This funding event signals strong investor confidence in Scala Biodesign's computational protein design technology and its potential to significantly impact the pharmaceutical and chemical industries by accelerating protein engineering timelines and overcoming complex development hurdles.
Log in to access full profile ›Company Intelligence Q&A
- When was Scala Biodesign founded?
- Scala Biodesign was founded in March 2022.
- Who are the founders of Scala Biodesign?
- The co-founders of Scala Biodesign are Ravit Netzer and Adi Goldenzweig.
- Which investors participated in Scala Biodesign's A Round?
- The A Round in March 2026 saw participation from lead investor Grove Ventures and TLV Partners.
- What is Scala Biodesign's primary focus?
- Scala Biodesign focuses on developing computational protein design solutions to address complex protein development challenges in various industries, including pharmaceuticals and chemicals.